TRANS GENIC GROUP INC. Logo

TRANS GENIC GROUP INC.

Biotech firm offering drug discovery support and investment/consulting services.

2342 | T

Overview

Corporate Details

ISIN(s):
JP3635720000
LEI:
Country:
Japan
Address:
福岡市中央区天神二丁目3番36号

Description

TRANS GENIC GROUP INC. is a biotechnology company that operates through two main business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support division provides comprehensive services across the entire drug development pipeline, from basic research to non-clinical and clinical trials. Core services include the contract production of genetically modified animals, particularly mice, using genome editing technologies like CRISPR/Cas9. The company also specializes in contract antibody production, glycosylation analysis, and the supply of model mice. The Investment & Consulting segment focuses on M&A, business succession, and providing advisory and support services for business revitalization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-11-13 02:42
四半期報告書-第23期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 203.7 KB
2020-08-13 04:19
四半期報告書-第23期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese 161.9 KB
2020-06-18 07:16
有価証券報告書-第22期(平成31年4月1日-令和2年3月31日)
Japanese 984.3 KB
2020-02-10 02:45
四半期報告書-第22期第3四半期(令和1年10月1日-令和1年12月31日)
Japanese 192.2 KB
2019-11-11 01:28
四半期報告書-第22期第2四半期(2019/07/01-2019/09/30)
Japanese 239.5 KB
2019-08-13 03:14
四半期報告書-第22期第1四半期(2019/04/01-2019/06/30)
Japanese 198.8 KB
2019-06-20 07:28
有価証券報告書-第21期(平成30年4月1日-平成31年3月31日)
Japanese 1.1 MB
2019-02-12 02:07
四半期報告書-第21期第3四半期(2018/10/01-2018/12/31)
Japanese 196.8 KB
2018-11-12 03:14
四半期報告書-第21期第2四半期(2018/07/01-2018/09/30)
Japanese 197.0 KB
2018-08-13 09:24
四半期報告書-第21期第1四半期(2018/04/01-2018/06/30)
Japanese 172.3 KB
2018-06-21 05:40
有価証券報告書-第20期(平成29年4月1日-平成30年3月31日)
Japanese 938.8 KB
2018-02-05 07:45
四半期報告書-第20期第3四半期(2017/10/01-2017/12/31)
Japanese 215.6 KB
2017-11-13 01:42
四半期報告書-第20期第2四半期(2017/07/01-2017/09/30)
Japanese 193.6 KB
2017-08-04 02:48
四半期報告書-第20期第1四半期(2017/04/01-2017/06/30)
Japanese 145.9 KB
2017-06-22 02:36
有価証券報告書-第19期(2016/04/01-2017/03/31)
Japanese 814.9 KB

Automate Your Workflow. Get a real-time feed of all TRANS GENIC GROUP INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TRANS GENIC GROUP INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TRANS GENIC GROUP INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.